GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand

With aging top dog losing ground to and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their own blockbuster sales. And new study comparing Advair with not-yet-launched Ellipta could help the fledgling COPD treatment do just that.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS